Hypothesis

In aged skeletal muscle, the metabolic benefits of L-carnitine supplementation depend on the cellular AMPK activity state: high AMPK activation inhibits carnitine uptake and limits fatty acid oxidation, whereas reduced AMPK signaling permits carnitine to restore shuttle flux and improve mitochondrial function.

Mechanistic rationale

Research shows that L-carnitine raises muscle carnitine pools and boosts fat oxidation by supplying substrate for the carnitine acetyltransferase (CAT) and carnitine palmitoyltransferase (CPT) enzymes, without invoking classic hormetic pathways like NRF2/AMPK[1,2]. Conversely, AMPK activators blunt L-carnitine transport in cultured myotubes[3] and lifespan extensions observed in C. elegans via SKN-1/DAF-16 do not translate to mammals, where carnitine alone fails to improve strength or body composition[4,5].

We propose that AMPK phosphorylates the organic cation transporter OCTN2 (the primary carnitine importer) or associated regulatory proteins, decreasing its Vmax or increasing its Km for carnitine. This post‑translational modification creates a substrate‑limiting bottleneck that cannot be overcome by merely increasing extracellular carnitine. When AMPK activity is low, OCTN2 operates at higher affinity, allowing supplemented carnitine to raise intracellular concentrations, thereby enhancing CPT1-mediated acyl‑carnitine formation and β‑oxidation.

Testable predictions

1. In aged mouse muscle, pharmacological AMPK inhibition (e.g., Compound C) will increase OCTN2-mediated carnitine uptake (measured by radiolabeled [^3H]-carnitine accumulation) by ≥30% relative to vehicle.
2. Combining L-carnitine supplementation with AMPK inhibition will produce a synergistic rise in muscle acetyl‑carnitine and CPT1 activity (>50% increase over carnitine alone) and elevate palmitate‑oxidation rates in isolated mitochondria.
3. Functional readouts—grip strength, treadmill endurance, and fatigue resistance—will improve significantly only in the group receiving both carnitine and AMPK inhibitor, not with either treatment alone.
4. Conversely, AMPK activation (AICAR or metformin) will blunt carnitine uptake and abolish the fat‑oxidation benefits of carnitine supplementation, resulting in no significant change versus control.

Experimental design (falsifiable)

• Subjects: 24‑month‑old C57BL/6J mice, n=10 per group.
• Groups: (1) Vehicle control, (2) L-carnitine (1 % w/w in diet), (3) AMPK inhibitor (Compound C, 10 mg/kg i.p. thrice weekly), (4) L-carnitine + AMPK inhibitor, (5) AMPK activator (AICAR, 250 mg/kg i.p. thrice weekly), (6) L-carnitine + AMPK activator.
• Duration: 12 weeks.
• Outcomes: muscle carnitine content (LC‑MS/MS), OCTN2 Vmax/Km (uptake assay), CPT1 activity (palmitoyl‑CoA oxidation), mitochondrial palmitate‑oxidation (Seahorse), grip strength, exhaustive treadmill run time.
• Statistical analysis: two‑way ANOVA with factors supplementation and AMPK modulation; interaction term tests synergy.

Falsifiability: If AMPK inhibition fails to increase carnitine uptake or does not synergize with carnitine to improve oxidative metabolism and functional performance, the hypothesis is refuted. Likewise, if AMPK activation does not diminish carnitine‑induced benefits, the proposed gating mechanism is invalid.